论文部分内容阅读
目的:通过通心络胶囊对载脂蛋白E基因敲除[(ApoE(-/-)]模型组小鼠血清血栓素B2(TXB2)、6-酮-前列腺素F1α(6-Keto-PGF1α)指标的干预变化,探究其防治冠心病(CHD)的机理。方法:将40只ApoE(-/-)小鼠作为实验组,建立高脂血症和冠状动脉粥样硬化(AS)模型,随机分为模型组等5组,分别给予辛伐他汀及不同剂量的通心络胶囊进行干预,另选8只同系的小鼠作为正常对照组。通过对模型组小鼠血清TXB2、6-Keto-PGF1α水平的观察,分析通心络胶囊对ApoE(-/-)小鼠冠状AS的调节作用和机理。结果:模型组ApoE(-/-)小鼠血清TXB2含量高于正常组,6-Keto-PGF1α含量低于正常组,与正常组相比均有统计学意义(P<0.05);通心络胶囊干预后,通心络胶囊高剂量组和辛伐他汀组与模型组相比,血清TXB2、6-Keto-PGF1α含量差异均有统计学意义(P<0.05);通心络胶囊高、中、低剂量组与辛伐他汀组相比,差异均无统计学意义(P>0.05)。结论:通心络胶囊能降低ApoE(-/-)小鼠血清TXB2、升高6-Keto-PGF1α水平,表明通心络胶囊具有抗凝,抑制血栓形成,达到恢复内皮功能,改善心肌缺血损伤,防治CHD的作用。
Objective: To investigate the effects of Tongxinluo capsule on the expression of TXB2, 6-Keto-PGF1α in apolipoprotein E knock-out mice [ApoE (- / - (CHD) .Methods: Forty ApoE (- / -) mice were used as the experimental group to establish hyperlipidemia and coronary atherosclerosis (AS) Divided into model group and other 5 groups, were given simvastatin and different doses of Tongxinluo capsule intervention, and the other 8 homologous mice as a normal control group.Through the model group of mice serum TXB2, 6-Keto- PGF1α in the ApoE (- / -) mice, and to investigate the regulatory effect and mechanism of Tongxinluo capsule on coronary AS in ApoE (- / -) mice.Results: The content of TXB2 in the model group was higher than that in the normal group Compared with the normal group, the content of -PGF1α was lower than that of the normal group (P <0.05). After Tongxinluo capsule intervention, compared with the model group, Tongxinluo capsule high-dose group and simvastatin group showed no significant difference TXB2 and 6-Keto-PGF1α were all significantly different (P <0.05). There was no significant difference between Tongxinluo Capsule group and simvastatin group (P> 0.05) ) Conclusion: Tongxinluo Capsule can reduce TXB2 and increase the level of 6-Keto-PGF1α in ApoE (- / -) mice, indicating that Tongxinluo Capsule has anticoagulation, inhibits thrombosis, restores endothelial function, Ischemic injury, the role of prevention and treatment of CHD.